- Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 studyJanjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Weber, P. E. Yanez; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Qin, S.; Van Cutsem, E.; Tabernero, J.; Li, K.; Shih, C-S.; Bhagia, P.; Rha, S. Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancerWyrwicz, L.; Oh, D.; Weber, P.; Bai, Y.; Ryu, M.; Lee, J.; Rivera, F.; Alves, G. Vasconcelos; Garrido, M.; Shiu, K.; Fernandez, M. Gonzalez; Li, J.; Lowery, M.; Cil, T.; Cruz, F.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Rha, S.
- KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populationsRha, Sun Young; Wyrwicz, Lucjan; Weber, Patricio Eduardo Yanez; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernandez, Manuel Gonzalez; Li, Jin; Lowery, Maeve Aine; Cil, Timucin; Cruz, Felipe Melo; Qin, Shukui; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Oh, Do-YounAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 4
会议论文
The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
5阅读
